DelveInisght launched a new report on Urea Cycle Disorders, Pipeline Insights 2021.
A Urea Cycle Disorder (UCD) is a genetic disorder that results in a deficiency of some major enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the bloodstream. The urea cycle involves a series of biochemical steps in which nitrogen, a waste product of protein metabolism, is changed to a compound called urea and removed from the blood.
Normally, the area is removed from the body through urine. In urea cycle disorders, nitrogen builds up in the blood in the form of ammonia, a highly toxic substance, resulting in hyperammonemia (elevated blood ammonia). Ammonia then reaches the brain through the blood, where it can cause irreversible brain damage, coma, and/or death. The onset and severity of urea cycle disorders are highly variable. The severity correlates with the amount of urea cycle enzyme function.
Request for sample pages of the report: https://www.delveinsight.com/sample-request/urea-cycle-disorders-pipeline-insight
“Urea Cycle Disorders Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Urea Cycle Disorders market. A detailed picture of the Urea Cycle Disorders pipeline landscape is provided, which includes the disease overview and Urea Cycle Disorders treatment guidelines.
Recent advances in the treatment of inborn errors of urea synthesis have significantly decreased the mortality rate. The treatment of urea cycle disorders consists of dietary management to limit ammonia production in conjunction with medications and/or supplements that provide alternative pathways for the removal of ammonia from the bloodstream.
The aims are to correct biochemical abnormalities and ensure adequate nutritional intake. Treatment involves compounds that increase the removal of nitrogen waste. These compounds convert nitrogen into products other than urea, which are then excreted; hence, the load on the urea cycle is reduced. The first compounds to be used were sodium benzoate and arginine.
Later, phenylacetate was used, which has now been replaced by phenylbutyrate.
1. Acer Therapeutics
2. Aeglea BioTherapeutics
4. Ultragenyx Pharmaceutical
Scope of the report:
- The Urea Cycle Disorders report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products
- It comprises detailed profiles of Urea Cycle Disorders therapeutic products with key coverage of developmental activities
- Detailed Urea Cycle Disorders research and development progress and trial details
- Coverage of dormant and discontinued pipeline projects
Download sample pages of the report: https://www.delveinsight.com/sample-request/urea-cycle-disorders-pipeline-insight
Table of contents:
1. Report Introduction
2. Urea Cycle Disorders
3. Urea Cycle Disorders Current Treatment Patterns
4. Urea Cycle Disorders – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Urea Cycle Disorders Late Stage Products (Phase-III)
7. Urea Cycle Disorders Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Urea Cycle Disorders Discontinued Products
13. Urea Cycle Disorders Product Profiles
14. Urea Cycle Disorders Key Companies
15. Urea Cycle Disorders Key Products
16. Dormant and Discontinued Products
17. Urea Cycle Disorders Unmet Needs
18. Urea Cycle Disorders Future Perspectives
19. Urea Cycle Disorders Analyst Review
21. Report Methodology
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States